Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
HSCS 
Heart Test Laboratories Inc. Common Stock (HSCS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: HSCS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.5
1 Year Target Price $10.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.38% | Avg. Invested days 15 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.45M USD | Price to earnings Ratio - | 1Y Target Price 10.5 |
Price to earnings Ratio - | 1Y Target Price 10.5 | ||
Volume (30-day avg) 2 | Beta 2.59 | 52 Weeks Range 2.52 - 6.47 | Updated Date 10/17/2025 |
52 Weeks Range 2.52 - 6.47 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.28 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -98637.84% |
Management Effectiveness
Return on Assets (TTM) -69.65% | Return on Equity (TTM) -193.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8925499 | Price to Sales(TTM) 1672.34 |
Enterprise Value 8925499 | Price to Sales(TTM) 1672.34 | ||
Enterprise Value to Revenue 1428.08 | Enterprise Value to EBITDA -0.14 | Shares Outstanding 3069635 | Shares Floating 2573920 |
Shares Outstanding 3069635 | Shares Floating 2573920 | ||
Percent Insiders 3.02 | Percent Institutions 1.96 |
Upturn AI SWOT
Heart Test Laboratories Inc. Common Stock
Company Overview
History and Background
Heart Test Laboratories Inc. (HSCS) focuses on developing and commercializing medical devices for early detection of heart disease. Founded with the goal of improving cardiac diagnostics, it aims to provide accessible and affordable heart health solutions.
Core Business Areas
- MyoVistau00aeWavelet ECG (MSECG): A resting 12-lead ECG with proprietary signal processing for enhanced cardiac risk assessment. This is their main revenue driver.
Leadership and Structure
Details on the specific leadership team and organizational structure are readily available on the company's investor relations page. Investors are recommended to perform their due diligence.
Top Products and Market Share
Key Offerings
- MyoVistau00aeWavelet ECG (MSECG): A resting 12-lead ECG with proprietary signal processing. Market share data is not publicly available due to the nascent stage of commercialization. Competitors include established ECG device manufacturers like GE Healthcare, Philips, and Nihon Kohden.
Market Dynamics
Industry Overview
The cardiovascular diagnostics market is large and growing, driven by an aging population and increasing prevalence of heart disease. It includes traditional ECGs, stress tests, and advanced imaging techniques.
Positioning
Heart Test Laboratories Inc. is positioning itself as a provider of advanced ECG technology that can improve early detection of heart disease. Its competitive advantage lies in its proprietary signal processing and machine learning algorithms that enhance the diagnostic capabilities of the traditional ECG.
Total Addressable Market (TAM)
The global ECG market is estimated to be in the billions of dollars. The TAM for Heart Test Laboratories Inc. is potentially large, but dependent on the successful commercialization and adoption of their technology by healthcare providers.
Upturn SWOT Analysis
Strengths
- Proprietary signal processing technology
- Potential for improved early detection of heart disease
- Relatively non-invasive diagnostic approach
Weaknesses
- Limited commercialization experience
- High dependence on successful product adoption
- Limited financial resources compared to larger competitors
- Low stock price could lead to delisting
Opportunities
- Partnerships with hospitals and clinics
- Expansion into new markets
- Development of new applications for its technology
- FDA Approval and reimbursement pathways to support product adoption
Threats
- Competition from established medical device companies
- Technological advancements by competitors
- Regulatory hurdles
- Challenges in securing reimbursement for its products
Competitors and Market Share
Key Competitors
- GE HealthCare Technologies Inc (GEHC)
- Koninklijke Philips NV (PHG)
- Nihon Kohden Corp (6849.T)
Competitive Landscape
Heart Test Laboratories Inc. faces significant competition from established medical device companies. Its success depends on differentiating its technology and securing market share.
Growth Trajectory and Initiatives
Historical Growth: Heart Test Laboratories Inc.'s historical growth is limited due to its early stage of commercialization.
Future Projections: Future growth projections depend on successful product adoption, market penetration, and execution of its business strategy.
Recent Initiatives: Highlight recent strategic initiatives undertaken by Heart Test Laboratories Inc., such as product development and marketing efforts. Investors should check company announcements.
Summary
Heart Test Laboratories Inc. is a developing company focused on improving cardiac diagnostics with its MSECG technology. Its technology shows promise, but the company faces challenges related to commercialization and competition. Its future success hinges on its ability to secure market adoption and execute its strategic initiatives. Securing funding and proving its tech is superior and less expensive than current diagnostics are key.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company press releases
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heart Test Laboratories Inc. Common Stock
Exchange NASDAQ | Headquaters Southlake, TX, United States | ||
IPO Launch date 2022-06-15 | CEO, President & Chairman of the Board of Directors Mr. Andrew Simpson | ||
Sector Healthcare | Industry Medical Devices | Full time employees 15 | Website https://heartsciences.com |
Full time employees 15 | Website https://heartsciences.com | ||
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.